Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 16/20 | 0.58 |
| ▸ | PSMB1 | P20618 | 12/20 | 0.54 |
| ▸ | PSMB2 | P49721 | 11/20 | 0.54 |
| ▸ | LONP1 | P36776 | 10/20 | 0.54 |
| ▸ | PSMB11 | A5LHX3 | 10/20 | 0.54 |
| ▸ | PSMA7 | O14818 | 10/20 | 0.54 |
| ▸ | PSMA1 | P25786 | 10/20 | 0.54 |
| ▸ | PSMA2 | P25787 | 10/20 | 0.54 |
| ▸ | PSMA3 | P25788 | 10/20 | 0.54 |
| ▸ | PSMA4 | P25789 | 10/20 | 0.54 |
| ▸ | PSMB8 | P28062 | 10/20 | 0.54 |
| ▸ | PSMB9 | P28065 | 10/20 | 0.54 |
| ▸ | PSMA5 | P28066 | 10/20 | 0.54 |
| ▸ | PSMB4 | P28070 | 10/20 | 0.54 |
| ▸ | PSMB6 | P28072 | 10/20 | 0.54 |
| ▸ | PSMB10 | P40306 | 10/20 | 0.54 |
| ▸ | PSMB3 | P49720 | 10/20 | 0.54 |
| ▸ | PSMA6 | P60900 | 10/20 | 0.54 |
| ▸ | PSMA8 | Q8TAA3 | 10/20 | 0.54 |
| ▸ | PSMB7 | Q99436 | 10/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18316389 | 1.00 | PSMB5 (0.58) | PSMB5PSMB1PSMB2LONP1PSMB11 | |
| SCHEMBL21210343 | 0.92 | PSMB5 (0.63) | PSMB5PSMB1PSMB2LONP1PSMB11 | |
| SCHEMBL21210524 | 0.92 | PSMB5 (0.63) | PSMB5PSMB1PSMB2LONP1PSMB11 | |
| SCHEMBL18316096 | 0.91 | PSMB5 (0.60) | PSMB5PSMB1PSMB2LONP1PSMB11 | |
| SCHEMBL18316099 | 0.91 | PSMB5 (0.60) | PSMB5PSMB1PSMB2LONP1PSMB11 | |
| SCHEMBL21194114 | 0.89 | PSMB5 (0.62) | PSMB5PSMB1PSMB2LONP1PSMB11 | |
| SCHEMBL21194531 | 0.89 | PSMB5 (0.62) | PSMB5PSMB1PSMB2LONP1PSMB11 | |
| SCHEMBL21194116 | 0.89 | PSMB5 (0.62) | PSMB5PSMB1PSMB2LONP1PSMB11 | |
| SCHEMBL21194061 | 0.89 | PSMB5 (0.62) | PSMB5PSMB1PSMB2LONP1PSMB11 | |
| SCHEMBL18316414 | 0.89 | PSMB5 (0.62) | PSMB5PSMB1PSMB2LONP1PSMB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325942-B2 | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis | BEIJING ARTIVILA BIOPHARMA CO. LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-11325942-B2 | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis | BEIJING ARTIVILA BIOPHARMA CO. LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-20210155658-A1 | CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS | ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| US-20210155658-A1 | CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS | ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| US-20190233470-A1 | CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS | ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) | 2019-08-01 | — | — | US | disclosed |
| US-10144761-B2 | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis | Hanlin Scientific Inc. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20160368945-A1 | CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS | ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368945-A1 | CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS | TBCA, BCL3, BCL6 | PSMB5 1303/4885PSMB1 1087/4885PSMB2 1445/4885 |
| US-20210155658-A1 | CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS | TBCA, BCL3, BCL6 | PSMB5 1303/4885PSMB1 1087/4885PSMB2 1445/4885 |
| US-10144761-B2 | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis | TBCA, BCL3, BCL6 | PSMB5 1303/4885PSMB1 1087/4885PSMB2 1445/4885 |
| US-11325942-B2 | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis | TBCA, BCL3, BCL6 | PSMB5 1303/4885PSMB1 1087/4885PSMB2 1445/4885 |
| US-20190233470-A1 | CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS | TBCA, BCL3, BCL6 | PSMB5 1303/4885PSMB1 1087/4885PSMB2 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.